BIOSENSE WEBSTER INC CARTO VIZIGO¿ 8.5F BI-DIRECTIONAL GUIDING SHEATH ¿ SMALL; INTRODUCER, CATHETER
|
Back to Search Results |
|
Model Number D138501 |
Device Problems
Material Separation (1562); Obstruction of Flow (2423)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 01/05/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|
|
Event Description
|
It was reported that a patient underwent an atrial fibrillation (afib) ablation procedure with a carto vizigo¿ 8.5f bi-directional guiding sheath ¿ small and the hemostatic valve separation occurred.It was reported by the caller that there was resistance when trying to advance the dilator through the vizigo sheath while prepping for the procedure.The caller noted that in trying to overcome the resistance the force applied damaged the hemostatic valve.The vizigo sheath was replaced and the issue was resolved.The procedure continued.There was no patient consequence.Additional information was received indicating the hemostatic valve was damaged.The hemostasis valve (gasket) did not break into two or more separate pieces.The hemostatic valve/brim cap/hub did become detached from the sheath.The sheath was not being used on the patient.There was resistance when the dilator was advanced through the sheath.There was no occlusion when irrigating the sheath.The sheath was not narrowed, partially blocked or completely blocked.The dilator was not able to be moved through the sheath.The dilator was not stuck on the sheath.There was no damage on dilator.The customer¿s reported issue of obstructed sheath is not considered to be mdr reportable since there is evidence of a product malfunction, as the device failed to meet its performance specification or otherwise performed as intended, however the potential that it could cause or contribute to a death or serious injury, or other significant adverse event, is remote.
|
|
Manufacturer Narrative
|
On (b)(6) 2022, the bwi product analysis lab received the complaint device for evaluation.The product analysis has begun but is not completed at this time.When the investigational analysis has been completed, a supplemental 3500a report will be submitted.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.#(b)(4).
|
|
Manufacturer Narrative
|
It was reported that a patient underwent an atrial fibrillation (afib) ablation procedure with a carto vizigo¿ 8.5f bi-directional guiding sheath ¿ small and the hemostatic valve separation occurred.It was reported by the caller that there was resistance when trying to advance the dilator through the vizigo sheath while prepping for the procedure.The caller noted that in trying to overcome the resistance the force applied damaged the hemostatic valve.The vizigo sheath was replaced and the issue was resolved.The procedure continued.There was no patient consequence.Device evaluation details: the device was returned to biosense webster inc (bwi) for evaluation and the evaluation has been completed.A visual inspection of the returned device were performed in accordance with bwi procedures.Visual analysis of the returned sample revealed that the hemostatic valve and silicone ring were not returned.The brim cap was placed in the correct position and found in good conditions.A device history record was performed and no internal action related to the reported complaint were identified.According to the odp (optimal performance guide), there are some precautions on inserting the dilator into the vizigo sheath: ¿always insert a dilator straight into the center of the sheath¿s valve to prevent damage to the valve.Do not insert a dilator at an angle, as damage to the sheath valve may occur.¿ as part of the quality process, all devices are manufactured, inspected, and released to approved specifications.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|
|
Search Alerts/Recalls
|
|
|